Jack P. Antel - Concepedia

Author

Jack P. Antel

Montreal Neurological Institute and Hospital ORCID

Also Known As

Antel, Jack, Antel, Jack P., Baiba K. Gillard, David Clifford, J Antel, J J ANTEL, J P Antel, J. ANTEL, J. Antel, J. P. ANTEL

754

Publications

57.8K

Citations

122

H-Index

267

Concepts

All Affiliations

Montreal Neurological Institute and Hospital McGill University University of Chicago Université de Montréal Centre Hospitalier de l’Université de Montréal

About

Jack P. Antel is an author at Montreal Neurological Institute and Hospital specializing in medicine, neuroimmunology, and neurology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	75	188	22.1K
2	Health Sciences	21	24	3.4K
3	Natural Sciences	6	6	690
4	Education	1	1	21
5	Engineering	1	1	93

Jack P. Antel

380

Publications

50.8K

Citations

111

H-Index

Page 1

	Year	Citations
Identification of a unique TGF-β–dependent molecular and functional signature in microglia Oleg Butovsky, Mark P. Jedrychowski, Craig S. Moore, Nature Neuroscience	2013	2.5K
B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis Stephen L. Hauser, Emmanuelle Waubant, Douglas L. Arnold, New England Journal of Medicine	2008	2.4K
Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor Veit Rothhammer, Iván Mascanfroni, Lukas Bunse, Nature Medicine InflammationMedicineAryl Hydrocarbon ReceptorImmunologyMicrobial Metabolites	2016	1.5K
iPSC-Derived Human Microglia-like Cells to Study Neurological Diseases Edsel M. Abud, Ricardo N. Ramírez, Eric S. Martinez, Neuron Neurodegenerative DiseasesNeurobiology Of DiseaseStudy Neurological DiseasesMedicineBrain-immune Interaction	2017	1.1K
Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis Ludwig Kappos, Jack P. Antel, Giancarlo Comi, New England Journal of Medicine	2006	1.1K
Microglial control of astrocytes in response to microbial metabolites Veit Rothhammer, Davis Borucki, Emily Tjon, Nature InflammationMedicineMicrobiotaBrain-immune InteractionNeuroscience	2018	1K
Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double‐blind placebo‐controlled multicenter trial Kathleen Hawker, Paul O’Connor, Mark S. Freedman, Annals of Neurology	2009	924
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study Ludwig Kappos, Amit Bar‐Or, Bruce Cree, The Lancet Neurological DisorderClinical NeurologyClinical TrialsSiponimod Versus PlaceboNeurological Monitoring	2018	896
Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis Tanja Kuhlmann, Véronique E. Miron, Q. Cuo, Brain Neurodegenerative DiseasesRemyelination FailureMedicineStem CellsNeural Stem Cell	2008	844
Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand Bibiana Bielekova, Bonnie L. Goodwin, Nancy Richert, Nature Medicine Neurodegenerative DiseasesEncephalitogenic PotentialNeurobiology Of DiseaseNeurological DisorderMedicine	2000	819

Page 1